Skip to main content

Advertisement

SpringerLink
Log in

HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India

  • Original Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Despite improvements in chemotherapy, survival of metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma remains poor. Trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), has shown promise in improving survival of these patients by a recent large phase III trial. HER2 status in gastric and GEJ cancers, although reported from across the world, is yet unknown in India due to lack of published literature from the country. HER2 status in 70 samples of gastric and GEJ adenocarcinomas (Siewert type III) was evaluated by immunohistochemistry (IHC) in this study using the gastric cancer scoring system. It was also correlated with clinic–pathologic factors. Samples with IHC score 2+ and 3+ were taken as HER2 positive. HER2 overexpression was found in 15 (21.4 %) samples, was significantly (p = 0.006) more common in intestinal type (45 %), but it did not correlate with age, gender, stage, or grade of tumor and did not affect the 2-year disease-free survival. HER2 overexpression is found only in a minority of patients with gastric and GEJ cancers in the Indian population. A large cohort of patients with a longer follow-up will be required to assess for any significant statistical association of HER2 expression with prognosis of these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. NCCN Clinical Practice Guidelines in Oncology. Gastric cancer. Version 2.2011. Accessed at www.nccn.org

  2. Krejs GJ (2010) Gastric cancer: epidemiology and risk factors. Dig Dis 28(4–5):600–603

    Article  PubMed  Google Scholar 

  3. Vial M, Grande L, Pera M (2010) Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res 182:1–17

    Article  PubMed  Google Scholar 

  4. NCRP (National Cancer Registry Programme). Consolidated report of population based cancer registries 2001–2004. Incidence and distribution of cancer. ICMR, Bangalore. 2006.

  5. Sastre J, García-Saenz JA, Díaz-Rubio E (2006) Chemotherapy for gastric cancer. World J Gastroenterol 12(2):2004–2213

    Google Scholar 

  6. Akiyama T, Sudo C, Ogawara H et al (1986) The product of the human c-erbB-2 gene: a 185-kilo-Dalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646

    Article  PubMed  CAS  Google Scholar 

  7. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  PubMed  CAS  Google Scholar 

  8. Kaptain S, Tan LK, Chen B (2001) Her-2/neu and breast cancer. Diagn Mol Pathol 10:139–152

    Article  PubMed  CAS  Google Scholar 

  9. Smith I, Procter M, Gelber RD et al (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36

    Article  PubMed  CAS  Google Scholar 

  10. Gravalos C, Jimino A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523–1529

    Article  PubMed  CAS  Google Scholar 

  11. Tanner M, Hollmen M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273–278

    Article  PubMed  CAS  Google Scholar 

  12. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697

    Article  PubMed  CAS  Google Scholar 

  13. Sawaki A, Ohashi Y, Omuro Y et al (2012) Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer 15(3):313–322

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Sekaran A, Kandagaddala RS, Darisetty S et al (2012) HER2 expression in gastric cancer in Indian population—an immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol 31(3):106–110

    Article  PubMed  Google Scholar 

  15. Patil PS, Mehta SA, Mohandas KM (2012) Over-expression of HER2 in Indian patients with gastric cancer. Indian J Gastroenterol. doi:10.1007/s12664-012-0279-9

  16. Wu B, Ye M, Chen H, Shen JF (2012) Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther 34(2):468–479

    Article  PubMed  Google Scholar 

  17. Moelans CB, van Diest PJ, Milne ANA, Offerhaus GJA (2011) Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2011:674182

    PubMed Central  Google Scholar 

  18. Sakai K, Mori S, Kawamoto T et al (1986) Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 77:1047–1052

    PubMed  CAS  Google Scholar 

  19. Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 2004;22:14S. Abstr 4053.

    Google Scholar 

  20. Park DI, Yun JW, Park JH et al (2006) HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371–1379

    Article  PubMed  CAS  Google Scholar 

  21. Kim KC, Koh YW, Chang HM et al (2011) Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18(10):2833–2840

    Article  PubMed  Google Scholar 

  22. Yonemura Y, Ninomiya I, Yamaguchi A et al (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51:1034–1038

    PubMed  CAS  Google Scholar 

  23. Nakajima M, Sawada H, Yamada Y et al (1999) The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 85:1894–1902

    Article  PubMed  CAS  Google Scholar 

  24. Grabsch H, Sivakumar S, Gray S et al (2010) HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series. Cell Oncol 32(1–2):57–65

    PubMed  Google Scholar 

  25. Kunz PL, Mojtahed A, Fisher GA et al (2012) HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 20(1):13–24. doi:10.1097/PAI.0b013e31821c821c

    Article  PubMed  CAS  Google Scholar 

  26. Berx G, Becker KF, Hofler H, van Roy F (1998) Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12:226–237

    Article  PubMed  CAS  Google Scholar 

  27. Park YS, Hwang HS, Park HJ et al (2012) Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43(3):413–422

    Article  PubMed  CAS  Google Scholar 

  28. Hofmann M, Stoss O, Shi D et al (2008) Assessment of HER2 scoring for gastric cancer: results from a validation study. Histopathology 52:797–805

    Article  PubMed  CAS  Google Scholar 

  29. Ruschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299–307

    Article  PubMed  PubMed Central  Google Scholar 

  30. FDA approval for trastuzumab—National Cancer Institute. www.cancer.gov/cancertopics/druginfo/fda-trastuzumab.

Download references

Author information

Author notes

  1. RR Mishra

    Present address: Department of Microbiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Authors and Affiliations

  1. Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221005, Uttar Pradesh, India

    Mallika Tewari, Akhileshwar Kumar, RR Mishra & Hari S Shukla

  2. Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Mohan Kumar

Authors
  1. Mallika Tewari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akhileshwar Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. RR Mishra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohan Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hari S Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hari S Shukla.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tewari, M., Kumar, A., Mishra, R. et al. HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India. Indian J Surg 77 (Suppl 2), 447–451 (2015). https://doi.org/10.1007/s12262-013-0871-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-013-0871-y

Keywords

Search

Navigation